首页> 外文期刊>Psychopharmacology >A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder
【24h】

A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder

机译:对精神分裂症或精神分裂症所致阿立哌唑加重的精神病症状加重的报道病例的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Rationale: Numerous case reports have suggested that aripiprazole can worsen psychotic symptoms in schizophrenia. Objectives: We reviewed reported cases which have suggested that aripiprazole can worsen psychotic symptoms in schizophrenia and evaluated each regarding quality of the causal relationship. Methods: A systematic literature search was conducted on August 18, 2012, using the PubMed and the EMBASE. Twenty-two cases met the following inclusion criteria: (1) diagnosis of schizophrenia or schizoaffective disorder, (2) worsening of psychotic symptoms associated with aripiprazole, and (3) aripiprazole dose ≤30 mg/day. Information about the causal relationship between aripiprazole and increased psychotic symptoms was extracted. The quality of the causal relationship was evaluated according to the modified guidelines for evaluation of drug-associated events and classified as "questionable, " "moderately suggestive," or "highly suggestive." Results: Patients were chronic in at least 15 cases, and prior antipsychotic dose exceeded recommended guidelines in 19 cases. Psychotic symptoms worsened after simply adding aripiprazole to the current regimen in eight cases. Besides psychotic symptoms, increasing agitation (nine cases), aggression (11 cases), and/or activation (seven cases) were reported. Clinical resolution occurred after aripiprazole discontinuation in eight cases. Regarding causal relationship, 11 cases were classified as "highly suggestive," three as "moderately suggestive," and eight as "questionable". Conclusions: Clinicians should be vigilant when adding aripiprazole to patients with chronic schizophrenia also receiving relatively high doses of other antipsychotics, and discontinuation of aripiprazole should be considered if psychotic symptoms and/or agitation/aggression/activation increase.
机译:理由:大量病例报告表明阿立哌唑可加重精神分裂症的精神病症状。目的:我们审查了报告的病例,这些病例表明阿立哌唑可加重精神分裂症的精神病症状,并就因果关系的质量进行了评估。方法:2012年8月18日使用PubMed和EMBASE进行系统的文献检索。 22例符合以下纳入标准:(1)精神分裂症或精神分裂症的诊断,(2)与阿立哌唑有关的精神病症状加重,和(3)阿立哌唑剂量≤30mg /天。提取了有关阿立哌唑与增加的精神病症状之间因果关系的信息。因果关系的质量根据修改后的药物相关事件评估指南进行评估,并分为“可疑”,“中度提示”或“高度提示”。结果:至少有15例患者为慢性患者,先前的抗精神病药物剂量超过了建议的指南19例。在八例患者中,仅在当前方案中添加阿立哌唑后,精神病症状就会恶化。除了精神病症状外,还报道了躁动加剧(9例),攻击性(11例)和/或激活(7例)。阿立哌唑停药后八例发生临床缓解。关于因果关系,将11例分类为“高度暗示”,三例分类为“中度暗示”,八例分类为“可疑”。结论:在患有慢性精神分裂症且也接受较高剂量其他抗精神病药的慢性精神分裂症患者中添加阿立哌唑时,临床医生应保持警惕,如果精神症状和/或激动/攻击/激活增加,则应考虑停用阿立哌唑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号